Keros Therapeutics Inc’s recent filing unveils that its Director GORDON CARL L unloaded Company’s shares for reported $11.0 million on Aug 13 ’24. In the deal valued at $44.01 per share,250,000 shares were sold. As a result of this transaction, GORDON CARL L now holds 119,522 shares worth roughly $1.33 million.
Then, ORBIMED ADVISORS LLC sold 250,000 shares, generating $11,002,500 in total proceeds. Upon selling the shares at $44.01, the Director now owns 119,522 shares.
Before that, OrbiMed Genesis Master Fund, L bought 29,400 shares. Keros Therapeutics Inc shares valued at $1,318,296 were divested by the Shareholder at a price of $44.84 per share.
Cantor Fitzgerald downgraded its Keros Therapeutics Inc [KROS] rating to a Neutral from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Wedbush’s analysts, who decreased its forecast for the stock in mid January from “an Outperform” to “a Neutral”. Oppenheimer also remained covering KROS and reiterated its “an Outperform” recommendation on December 16, 2024. Guggenheim revised its rating on December 16, 2024. It rated KROS as “a Neutral” which previously was an “a Buy”.
Price Performance Review of KROS
On Monday, Keros Therapeutics Inc [NASDAQ:KROS] saw its stock fall -2.37% to $11.13. Over the last five days, the stock has lost -2.79%. Keros Therapeutics Inc shares have fallen nearly -29.69% since the year began. Nevertheless, the stocks have fallen -79.90% over the past one year. While a 52-week high of $73.00 was reached on 01/02/25, a 52-week low of $9.77 was recorded on 01/15/25. SMA at 50 days reached $29.21, while 200 days put it at $46.97.
Levels Of Support And Resistance For KROS Stock
The 24-hour chart illustrates a support level at 11.00, which if violated will result in even more drops to 10.86. On the upside, there is a resistance level at 11.31. A further resistance level may holdings at 11.48. The Relative Strength Index (RSI) on the 14-day chart is 25.08, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.03, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 58.44%. Stochastics %K at 39.50% indicates the stock is a holding.
How much short interest is there in Keros Therapeutics Inc?
A steep rise in short interest was recorded in Keros Therapeutics Inc stocks on 2025-01-15, growing by 0.99 million shares to a total of 4.02 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 3.03 million shares. There was a rise of 24.71%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 13, 2024 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $47.